US1538678A
(en)
*
|
1923-02-24 |
1925-05-19 |
Joseph S Blinn |
Suppository injector
|
US3791385A
(en)
*
|
1972-10-16 |
1974-02-12 |
A Davis |
Catamenial device and applicator thereof
|
CA1339210C
(en)
|
1988-05-31 |
1997-08-05 |
John Lewicki |
Recombinant techniques for production of novel natriuretic and vasodilator peptides
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
US5352770A
(en)
|
1990-04-20 |
1994-10-04 |
Hisayuki Matsuo |
Porcine derived novel physiologically active peptide
|
JP2930380B2
(ja)
|
1990-07-13 |
1999-08-03 |
壽之 松尾 |
ブタ由来新規生理活性ペプチド(cnp―53)
|
JP3026351B2
(ja)
|
1990-07-13 |
2000-03-27 |
壽之 松尾 |
ブタcnp遺伝子及び前駆体蛋白
|
JP2977159B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
カエル由来新規生理活性ペプチド(カエルcnp)
|
JP2977158B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
トリ由来新規生理活性ペプチド(ニワトリcnp)
|
JP3026352B2
(ja)
|
1990-09-11 |
2000-03-27 |
壽之 松尾 |
ラットCNPcDNA及び前駆体蛋白
|
JP3026354B2
(ja)
|
1990-09-27 |
2000-03-27 |
壽之 松尾 |
ヒトcnp遺伝子及び前駆体蛋白
|
JP2809533B2
(ja)
|
1991-01-31 |
1998-10-08 |
壽之 松尾 |
Cnp類似体ペプチド
|
AU662155B2
(en)
*
|
1991-05-10 |
1995-08-24 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
WO1994020534A1
(en)
|
1993-03-03 |
1994-09-15 |
Mayo Foundation For Medical Education And Research |
Vasonatrin peptide and analogs thereof
|
AU4835693A
(en)
|
1993-08-13 |
1995-03-14 |
Rijksuniversiteit Te Groningen |
Pharmaceutical composition comprising phosphatase or a derivative thereof
|
US6525022B1
(en)
|
1993-11-12 |
2003-02-25 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US5665704A
(en)
|
1993-11-12 |
1997-09-09 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US5846932A
(en)
|
1993-11-12 |
1998-12-08 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
WO1995013296A1
(en)
|
1993-11-12 |
1995-05-18 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
ATE226960T1
(de)
|
1994-06-02 |
2002-11-15 |
Forssmann Wolf Georg |
Verfahren zur herstellung von cardiodilatin- fragmenten, hochgereinigte cardiodilatin- fragmente und zwischenprodukte zu deren herstellung
|
JPH0870875A
(ja)
|
1994-09-05 |
1996-03-19 |
Tosoh Corp |
組換えアルカリフォスファタ−ゼ融合タンパク質
|
US5863782A
(en)
*
|
1995-04-19 |
1999-01-26 |
Women's And Children's Hospital |
Synthetic mammalian sulphamidase and genetic sequences encoding same
|
ZA979060B
(en)
|
1996-10-22 |
1999-04-09 |
Genentech Inc |
Receptor selective BNP
|
US6028055A
(en)
|
1996-10-22 |
2000-02-22 |
Genetech, Inc. |
Receptor selective BNP
|
WO1998035703A2
(en)
*
|
1997-02-14 |
1998-08-20 |
The Salk Institute For Biological Studies |
Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
|
WO1999046283A1
(en)
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
CA2245903A1
(en)
*
|
1998-09-28 |
2000-03-28 |
Mcgill University |
Use of pex in the treatment of metabolic bone diseases
|
CA2260376A1
(en)
|
1999-02-11 |
2000-08-11 |
Universite De Montreal |
New metalloproteases of the neprilysin family
|
CA2262056A1
(en)
*
|
1999-02-24 |
2000-08-24 |
Guy Boileau |
Composition, methods and reagents for the synthesis of a soluble form of human pex
|
AU2495200A
(en)
|
1999-03-08 |
2000-09-28 |
Genentech Inc. |
Compositions and methods for the treatment of tumor
|
WO2000064486A2
(en)
|
1999-04-28 |
2000-11-02 |
Vectramed, Inc. |
Enzymatically activated polymeric drug conjugates
|
CA2623458A1
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem Biotechnologies Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
JP2000327583A
(ja)
*
|
1999-05-17 |
2000-11-28 |
Medei Sci Puraningu:Kk |
骨指向性ホルモン誘導体
|
US20040266673A1
(en)
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
DE19942230C2
(de)
|
1999-09-03 |
2003-09-25 |
Wolf-Georg Forssmann |
Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
|
EP1818407A3
(en)
|
1999-11-16 |
2007-08-29 |
Genzyme Corporation |
Improved regulatory elements for delivery to the liver
|
US20020103161A1
(en)
|
1999-12-17 |
2002-08-01 |
Manfred Weigele |
Novel heterocycles
|
US6407211B1
(en)
|
1999-12-17 |
2002-06-18 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides
|
JP4237375B2
(ja)
|
2000-03-31 |
2009-03-11 |
アスビオファーマ株式会社 |
虚血性疾患の処置又は予防に用いる医薬組成物
|
US7678391B2
(en)
|
2000-04-26 |
2010-03-16 |
Queen's University At Kingston |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
US20050142217A1
(en)
|
2000-04-26 |
2005-06-30 |
Adams Michael A. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
US6946484B2
(en)
|
2000-04-26 |
2005-09-20 |
Cellegy Pharmaceuticals, Inc. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
EP1502604A1
(en)
|
2000-04-26 |
2005-02-02 |
Cellegy Pharmaceuticals, Inc |
Use of nitric oxide mimetics in cancer treatment
|
US6830885B1
(en)
|
2000-08-18 |
2004-12-14 |
Phenogene Therapeutiques Inc. |
Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
|
EP1311691B1
(en)
|
2000-08-23 |
2006-10-04 |
Enobia Pharma Inc. |
Method and compositions for promoting osteogenesis
|
US6436386B1
(en)
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
KR100942864B1
(ko)
|
2000-12-07 |
2010-02-17 |
일라이 릴리 앤드 캄파니 |
Glp-1 융합 단백질
|
JP2002178279A
(ja)
|
2000-12-12 |
2002-06-25 |
Ulvac Japan Ltd |
基板搬送方法
|
AU2002255478A1
(en)
*
|
2001-01-10 |
2002-09-12 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
JP2002246704A
(ja)
|
2001-02-16 |
2002-08-30 |
Philips Japan Ltd |
電子装置及び回路装置
|
IL142118A0
(en)
|
2001-03-20 |
2002-03-10 |
Prochon Biotech Ltd |
Method and composition for treatment of skeletal dysplasias
|
WO2002092020A2
(en)
*
|
2001-03-23 |
2002-11-21 |
The Burnham Institute |
Compositions and methods for modulating bone mineral deposition
|
US7888372B2
(en)
*
|
2001-03-23 |
2011-02-15 |
National Institutes Of Health (Nih) |
Compositions and methods for modulating bone mineral deposition
|
DE60233047D1
(de)
*
|
2001-05-14 |
2009-09-03 |
Gbp Ip Llc |
Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
|
JP3935487B2
(ja)
|
2001-07-16 |
2007-06-20 |
フーベルト・ケスター |
捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法
|
US6610025B2
(en)
*
|
2001-08-06 |
2003-08-26 |
The Procter & Gamble Company |
Tampon applicator arrangement
|
BRPI0203172B8
(pt)
|
2001-09-28 |
2021-05-25 |
Nakao Kazuwa |
composição farmacêutica para acondroplasia
|
US20050202442A1
(en)
|
2003-12-15 |
2005-09-15 |
Morris David W. |
Novel therapeutic targets in cancer
|
CA2469972A1
(en)
|
2001-12-20 |
2003-07-03 |
Phenogene Therapeutiques Inc. |
Bone polypeptide-1
|
JP5424521B2
(ja)
|
2001-12-21 |
2014-02-26 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
アルブミン融合タンパク質
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
US20030158132A1
(en)
*
|
2002-01-22 |
2003-08-21 |
Genvec, Inc. |
Method for enhancing bone density or formation
|
CA2478145A1
(en)
|
2002-03-06 |
2003-09-12 |
Cellegy Pharmaceuticals, Inc. |
Formulations and methods of using nitric oxide mimetics in cancer treatment
|
US20040077537A1
(en)
|
2002-03-18 |
2004-04-22 |
Schreiner George F. |
Method for treating congestive heart failure
|
US20050113286A1
(en)
|
2002-03-18 |
2005-05-26 |
Schreiner George F. |
Methods for treating congestive heart failure
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
CA2433479A1
(en)
*
|
2002-07-22 |
2004-01-22 |
F. Hoffmann-La Roche Ag |
Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
|
JP2006514607A
(ja)
|
2002-07-31 |
2006-05-11 |
コンジュケム,インコーポレーテッド |
長時間持続性ナトリウム***増加性ペプチド誘導体
|
WO2004022579A2
(en)
|
2002-09-06 |
2004-03-18 |
University Of South Florida |
Cellular delivery of natriuretic peptides
|
EP1562990B1
(en)
|
2002-11-18 |
2010-07-21 |
Syn X Pharma, Inc. |
Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
|
US7648962B2
(en)
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
AU2003297583B2
(en)
|
2002-11-26 |
2010-01-14 |
Biocon, Ltd |
Modified naturetic compounds, conjugates, and uses thereof
|
US7105539B2
(en)
|
2002-12-03 |
2006-09-12 |
Enobia Pharma |
Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
|
WO2004062555A2
(en)
|
2003-01-13 |
2004-07-29 |
Gudrun Rappold-Hoerbrand |
Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
|
JP2009520459A
(ja)
|
2003-02-14 |
2009-05-28 |
サイグレス ディスカバリー, インコーポレイテッド |
癌における治療標的
|
US7488713B2
(en)
|
2004-03-18 |
2009-02-10 |
University Of South Florida |
Cancer treatment using C-type natriuretic peptides
|
JP2006527190A
(ja)
|
2003-04-17 |
2006-11-30 |
サイファージェン バイオシステムズ インコーポレイテッド |
ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法
|
AU2004257142A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
CA2570398C
(en)
|
2003-06-17 |
2020-05-12 |
Otago Innovation Limited |
Assessment of skeletal growth using measurements of nt-cnp peptides
|
ATE485303T1
(de)
|
2003-06-20 |
2010-11-15 |
Mayo Foundation |
Isoformen von gehirn-natriuretischem peptid
|
WO2005052593A1
(en)
|
2003-10-29 |
2005-06-09 |
The University Of Leicester |
Detection
|
US7431915B2
(en)
|
2003-10-31 |
2008-10-07 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
PL2256134T3
(pl)
*
|
2003-11-13 |
2014-06-30 |
Hanmi Science Co Ltd |
Fragment Fc Ig do nośnika leku i sposób jego wytwarzania
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
WO2005070446A1
(en)
|
2004-01-15 |
2005-08-04 |
Scios Inc. |
Method for treating cardiac remodeling following myocardial injury
|
US20080182299A1
(en)
|
2004-01-27 |
2008-07-31 |
Compugent Ltd. |
Novel brain natriuretic peptide variants and methods of use thereof
|
AU2005207886A1
(en)
|
2004-01-27 |
2005-08-11 |
Compugen Usa, Inc. |
Novel brain natriuretic peptide variants and methods of use thereof
|
EP3446711A1
(en)
|
2004-03-31 |
2019-02-27 |
Kazuwa Nakao |
Composition for increasing body height
|
EP1759710B1
(en)
|
2004-03-31 |
2014-05-07 |
Kazuwa Nakao |
Remedy or preventive for arthritis
|
JP2005292718A
(ja)
|
2004-04-05 |
2005-10-20 |
Furukawa Electric Co Ltd:The |
光導波路、光導波路モジュールおよび光導波路の作成方法
|
AU2005235635B2
(en)
|
2004-04-21 |
2010-11-18 |
Alexion Pharmaceuticals, Inc. |
Bone delivery conjugates and method of using same to target proteins to bone
|
JP2007537263A
(ja)
|
2004-05-10 |
2007-12-20 |
ノバセア インコーポレイティッド |
活性ビタミンd化合物による動脈再狭窄の予防法
|
US7863238B2
(en)
*
|
2004-06-10 |
2011-01-04 |
Saint Louis University |
Proteins with an attached short peptide of acidic amino acids
|
US20070081984A1
(en)
*
|
2005-10-11 |
2007-04-12 |
Shunji Tomatsu |
Compositions and methods for treating hypophosphatasia
|
US20070081986A1
(en)
|
2005-10-07 |
2007-04-12 |
Shunji Tomatsu |
Beta-glucuronidase with an attached short peptide of acidic amino acids
|
US7972593B2
(en)
*
|
2004-06-10 |
2011-07-05 |
Saint Louis University |
Delivery of therapeutic agents to the bone
|
ATE496060T1
(de)
|
2004-07-15 |
2011-02-15 |
Univ Queensland |
Proteinartige verbindungen und anwendungen davon
|
US20090142347A1
(en)
*
|
2004-09-29 |
2009-06-04 |
The Burnham Institute For Medical Research |
Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
|
MX2007006524A
(es)
|
2004-12-01 |
2007-06-22 |
Genzyme Corp |
Metodos para el suministro dirigido de material genetico al higado.
|
DK1865976T3
(da)
|
2005-04-07 |
2012-07-23 |
Cardiopep Pharma Gmbh |
Anvendelse af natriuretiske peptider til behandling af hjertesvigt
|
EP1874816A4
(en)
|
2005-04-26 |
2010-08-25 |
Medimmune Inc |
MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
|
US20070042957A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Mayo Foundation For Medical Education And Research |
Type v phosphodiesterase inhibitors and natriuretic polypeptides
|
US7470668B2
(en)
|
2005-08-24 |
2008-12-30 |
Enobia Pharma Inc. |
Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
|
EP1933863A4
(en)
|
2005-09-06 |
2010-06-09 |
Zelos Therapeutics Inc |
PARATHYROIDIAN HORMONE ANALOGS AND METHODS USING SAME
|
WO2007035600A2
(en)
|
2005-09-16 |
2007-03-29 |
Mayo Foundation For Education And Research |
Natriuretic activities
|
WO2007041645A2
(en)
|
2005-10-03 |
2007-04-12 |
Scios Inc. |
Oxidized human bnp
|
RU2316334C2
(ru)
|
2005-12-19 |
2008-02-10 |
Медитек Индастриз ЛЛС |
Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
CA2638912A1
(en)
|
2006-02-20 |
2007-08-30 |
Phylogica Limited |
Method of constructing and screening libraries of peptide structures
|
US8784833B2
(en)
|
2006-06-27 |
2014-07-22 |
Saint Louis University |
Prenatal enzyme replacement therapy for hypophosphatasia
|
EP2040758A4
(en)
|
2006-06-30 |
2014-09-17 |
Interface Biologics Inc |
BIORESPONSIVE POLYMERS
|
US8324162B2
(en)
|
2006-08-08 |
2012-12-04 |
Mayo Foundation For Medical Education And Research |
Diuretic and natriuretic polypeptides lacking the blood pressure lowering property
|
US7825092B2
(en)
|
2006-08-08 |
2010-11-02 |
University Of South Florida |
Dendroaspis natriuretic peptide for treatment of cancer
|
EP2069396B1
(en)
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
MX2009002504A
(es)
|
2006-09-08 |
2009-05-22 |
Mayo Foundation |
Polipeptidos acuareticos y natriureticos que carecen de actividad vasodilatadora.
|
US8043829B2
(en)
*
|
2006-10-25 |
2011-10-25 |
Amgen Inc. |
DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
|
WO2008058016A2
(en)
|
2006-11-02 |
2008-05-15 |
University Of Virginia Patent Foundation |
Ethoid-containing compounds, methods for preparing ethoid-containing compounds, and methods for use
|
CN101668421B
(zh)
|
2006-11-16 |
2014-05-21 |
凯制药公司 |
用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
|
US20080181903A1
(en)
*
|
2006-12-21 |
2008-07-31 |
Pdl Biopharma, Inc. |
Conjugate of natriuretic peptide and antibody constant region
|
EP2118665B1
(en)
|
2007-03-12 |
2012-04-18 |
Biomedica Medizinprodukte GmbH & Co KG |
Diagnosis of septic complications
|
EP1985697A1
(en)
|
2007-04-27 |
2008-10-29 |
AM-Pharma B.V. |
Modified phosphatases
|
KR20080098216A
(ko)
|
2007-05-04 |
2008-11-07 |
한미약품 주식회사 |
캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
|
PT2662448T
(pt)
*
|
2007-05-11 |
2017-03-29 |
Alexion Pharma Inc |
Fosfatase alcalina dirigida ao osso, kits e métodos para a utilização da mesma
|
NZ581395A
(en)
|
2007-05-14 |
2012-08-31 |
Biogen Idec Inc |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
JP2010530222A
(ja)
|
2007-06-06 |
2010-09-09 |
べーリンガー インゲルハイム インターナショナル ゲーエムベーハー |
ナトリウム利尿融合タンパク質
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
WO2009006520A1
(en)
|
2007-07-03 |
2009-01-08 |
Medimmune, Llc |
Hinge domain engineering
|
MX2009013372A
(es)
|
2007-07-06 |
2010-02-22 |
Theratechnologies Inc |
Proteinas de fusion bifuncionales de la hormona estimulante de alfa-melanocitos (alfa-msh) y proteina natriuretica atrial (anp) y usos en hipertension y lesion de riñon aguda.
|
WO2009015011A1
(en)
|
2007-07-20 |
2009-01-29 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
CA2696113A1
(en)
|
2007-08-10 |
2009-04-02 |
Burnham Institute For Medical Research |
Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
|
CN103298935A
(zh)
|
2007-08-15 |
2013-09-11 |
阿穆尼克斯公司 |
用于改善生物活性多肽性能的组合物和方法
|
KR20100063716A
(ko)
|
2007-09-11 |
2010-06-11 |
몬도바이오테크 래보래토리즈 아게 |
치료제로서 사용하기 위한 아스트레신 및 베타-엔도르핀
|
EP2187941A2
(en)
|
2007-09-11 |
2010-05-26 |
Mondobiotech Laboratories AG |
Use of a galanin peptide as a therapeutic agent
|
WO2009033807A2
(en)
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
|
EP2187921A2
(en)
|
2007-09-11 |
2010-05-26 |
Mondobiotech Laboratories AG |
Use of gonadorelin as a therapeutic agent
|
EP2190535B1
(en)
|
2007-09-11 |
2012-08-08 |
Mondobiotech Laboratories AG |
Somatostatin-14 for use in the prophylaxis and/or treatment of HBV
|
ES2575397T3
(es)
|
2007-09-11 |
2016-06-28 |
Cardiopep Pharma Gmbh |
Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
|
US8357656B2
(en)
|
2007-09-15 |
2013-01-22 |
Mayo Foundation For Medical Education And Research |
Natriuretic peptide receptor-C agonists
|
EP2217620A2
(en)
|
2007-11-21 |
2010-08-18 |
BioMarin Pharmaceutical Inc. |
Variants of c-type natriuretic peptide
|
WO2009086126A2
(en)
|
2007-12-21 |
2009-07-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
PL2277890T3
(pl)
|
2008-05-23 |
2016-06-30 |
Daiichi Sankyo Co Ltd |
Peptyd zdolny do wydłużenia czasu półtrwania w osoczu peptydu będącego przedmiotem zainteresowania
|
CN102143757A
(zh)
|
2008-06-06 |
2011-08-03 |
梅约医学教育与研究基金会 |
嵌合利尿钠多肽和抑制心脏重构的方法
|
WO2009156481A1
(en)
|
2008-06-25 |
2009-12-30 |
Ascendis Pharma As |
Pegylated bnp
|
US20100015144A1
(en)
|
2008-06-26 |
2010-01-21 |
Acceleron Pharma Inc. |
Methods for dosing an activin-actriia antagonist and monitoring of treated patients
|
US8741842B2
(en)
|
2008-07-02 |
2014-06-03 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic polypeptides with unique pharmacologic profiles
|
UA101670C2
(ru)
|
2008-07-23 |
2013-04-25 |
Ханми Сайенс Ко., Лтд. |
Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца
|
US20100093678A1
(en)
|
2008-10-10 |
2010-04-15 |
The University Of Georgia Research Foundation, Inc |
Compositions and methods of the treatment of obesity and osteoporosis
|
US8642550B2
(en)
|
2008-10-24 |
2014-02-04 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides without hypotensive inducing capability
|
WO2010078325A2
(en)
|
2008-12-29 |
2010-07-08 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides for reducing or preventing restenosis
|
AR075029A1
(es)
|
2009-01-19 |
2011-03-02 |
Hanmi Pharm Ind Co Ltd |
Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina
|
JP2012521784A
(ja)
|
2009-03-30 |
2012-09-20 |
ベーリンガー・インゲルハイム・インテルナツィオナール・ゲーエムバーハー |
イヌFc部分を含む融合タンパク質
|
US20120053123A1
(en)
|
2009-05-05 |
2012-03-01 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides having mutations within their disulfide rings
|
KR102033680B1
(ko)
|
2009-05-20 |
2019-10-18 |
바이오마린 파머수티컬 인크. |
씨형 나트륨이뇨 펩티드의 변이체
|
AU2011245005A1
(en)
|
2010-04-30 |
2012-11-22 |
Alexion Pharma Holding |
Methods, compositions, and kits for the treatment of matrix mineralization disorders
|
AU2011350066A1
(en)
|
2010-12-27 |
2013-07-11 |
Alexion Pharma International Sarl |
Compositions comprising natriuretic peptides and methods of use thereof
|
WO2013058833A1
(en)
|
2011-10-19 |
2013-04-25 |
Enobia Canada Limited Partnership |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
JP6204369B2
(ja)
|
2011-11-10 |
2017-09-27 |
カイ・ファーマシューティカルズ・インコーポレイテッドKai Pharmaceuticals,Inc. |
カルシウム模倣薬およびその使用方法
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
KR20150073944A
(ko)
|
2012-07-25 |
2015-07-01 |
싸이오서스 테라퓨틱스 엘티디. |
악액질 및 근육감소증 치료를 위한 s핀돌롤의 사용
|
CA2936829A1
(en)
|
2014-01-24 |
2015-07-30 |
Am-Pharma B.V. |
Downstream processing of an alkaline phosphatase
|
ES2851674T3
(es)
|
2014-06-09 |
2021-09-08 |
Ultragenyx Pharmaceutical Inc |
Control efectivo y eficaz de fosfato sérico para una formación ósea óptima
|
US10822596B2
(en)
|
2014-07-11 |
2020-11-03 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for treating craniosynostosis
|
KR20170095278A
(ko)
|
2014-12-05 |
2017-08-22 |
알렉시온 파마슈티칼스, 인코포레이티드 |
재조합 알칼리성 포스파타제를 이용한 발작 치료
|
AU2016211447B2
(en)
|
2015-01-28 |
2021-09-23 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
WO2017031114A1
(en)
|
2015-08-17 |
2017-02-23 |
Alexion Pharmaceuticals, Inc. |
Manufacturing of alkaline phosphatases
|
WO2017058822A1
(en)
|
2015-09-28 |
2017-04-06 |
Alexion Pharmaceuticals, Inc. |
Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
|
WO2017074466A1
(en)
|
2015-10-30 |
2017-05-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating craniosynostosis in a patient
|
US11065306B2
(en)
|
2016-03-08 |
2021-07-20 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
WO2017171871A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
WO2017173395A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
US11186832B2
(en)
|
2016-04-01 |
2021-11-30 |
Alexion Pharmaceuticals, Inc. |
Treating muscle weakness with alkaline phosphatases
|
WO2017214130A1
(en)
|
2016-06-06 |
2017-12-14 |
Alexion Pharmaceuticals, Inc. |
Metal impact on manufacturing of alkaline phosphatases
|
WO2018004517A1
(en)
|
2016-06-27 |
2018-01-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children and adolescents
|
JP7018933B2
(ja)
|
2016-08-18 |
2022-02-14 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
気管気管支軟化症の治療方法
|